Technologies for Improving Minority Health and Eliminating Health Disparities (R41/R42- Clinical Trial Optional) | RFA MD 22 003

Opportunity Information: Apply for RFA MD 22 003

The funding opportunity titled "Technologies for Improving Minority Health and Eliminating Health Disparities (R41/R42 - Clinical Trial Optional)" is a National Institutes of Health (NIH) Small Business Technology Transfer (STTR) grant program designed to move practical health technologies toward commercialization. The core purpose is to support U.S. small business concerns in developing a product, process, or service that can improve minority health and reduce, and ultimately eliminate, health disparities in one or more NIH-defined populations that experience health disparities. In plain terms, this FOA is looking for solutions that are not just scientifically interesting, but realistically deployable in the real world and capable of making measurable progress in closing gaps in health outcomes.

This is an STTR mechanism, meaning the small business applicant is expected to work in partnership with a research institution as part of the development effort. The specific activity codes referenced are R41 and R42, which generally correspond to a phased approach: an early stage proof-of-concept or feasibility phase (R41) followed by a later stage development phase (R42) aimed at advancing the technology toward commercialization and broader impact. The announcement notes that clinical trials are optional, which signals flexibility: applicants can propose projects that involve clinical testing if it is appropriate for the technology and stage of development, but they are not required to do so. That makes the opportunity relevant to a wide range of projects, including tools that are preclinical or implementation-focused, as well as technologies that need clinical evaluation.

A central theme in this FOA is that the proposed technology should be effective, affordable, and culturally acceptable for the communities it is intended to serve. This is more than general language about impact; it sets an expectation that applicants think beyond technical performance and address real adoption barriers. "Affordable" and "culturally acceptable" points toward solutions that can realistically be used in settings that may be under-resourced, and that fit the needs, preferences, and lived realities of populations facing disparities. Strong applications would typically connect the technology to a specific disparity problem, explain why current approaches fall short, and show how the proposed product or service is designed to work within the constraints of real care environments and community contexts.

Eligibility is restricted to eligible United States small business concerns, consistent with STTR requirements. Foreign institutions are not eligible to apply, and non-U.S. components of U.S. organizations are also not eligible to apply. However, the FOA indicates that "foreign components," as defined in the NIH Grants Policy Statement, may be allowed in some circumstances, which usually means a limited, well-justified part of the work could be conducted abroad if it is essential and meets NIH policy requirements. The key takeaway is that the applicant organization must be a U.S. small business, and the project should be structured primarily as a U.S.-based effort with any foreign involvement carefully constrained and justified under NIH rules.

From the administrative details provided, the opportunity is a discretionary grant under NIH, with the Funding Opportunity Number RFA-MD-22-003. It falls under the health funding activity category and references CFDA numbers 93.307 and 93.350, which correspond to NIH funding streams associated with minority health and health disparities research and related programs. The original closing date listed is April 4, 2022, and the FOA creation date is January 5, 2022. The award ceiling, expected award count, and similar fields are not specified in the provided source data, so applicants would normally confirm budget limits, project period allowances, and the anticipated number of awards in the full FOA text.

Overall, this FOA is best understood as NIH support for commercialization-oriented technology development that directly targets health disparities. It emphasizes practical, community-relevant solutions and encourages applicants to build technologies with a clear pathway to real-world use, including considerations like cost, accessibility, and cultural fit, while leveraging the STTR model to pair small business innovation with research partner expertise.

• The National Institutes of Health in the health sector is offering a public funding opportunity titled "Technologies for Improving Minority Health and Eliminating Health Disparities (R41/R42- Clinical Trial Optional)" and is now available to receive applicants.
• Interested and eligible applicants and submit their applications by referencing the CFDA number(s): 93.307, 93.350.
• This funding opportunity was created on 2022-01-05.
• Applicants must submit their applications by 2022-04-04. (Agency may still review applications by suitable applicants for the remaining/unused allocated funding in 2026.)
• Eligible applicants include: Small businesses.

Apply for RFA MD 22 003

[Watch] Creating a grant proposal using the step-by-step wizard inside the applicant portal: